Smith & Nephew Plc of the UK is acquiring ArthroCare Corp of the US in a move that will strengthen its position in sports medicine. The value of the deal is $1.7 billion, or about $1.5 billion when ArthroCare’s cash reserves are taken into account.
Crossject SA, a French company with a needle-free pharmaceutical injection system designed for self-administration, is issuing 1,538,462 shares in an initial public offering on the NYSE Alternext exchange in Paris.
Ablynx NV has secured a new research collaboration with Merck & Co based on its technology for antibody-derived therapeutic proteins – this time to discover and develop candidate drugs th
Germany-based Medigene AG, which has a long history in oncology drug discovery, has acquired Trianta Immunotherapies GmbH of Munich, a spin-out with three T cell immunotherapy technologies. The value of the deal is €4 million plus milestones.
Genmab A/S has raised DKK 998 million (€134 million) following the pricing of a previously-announced private share placement to support development of its therapeutic antibody portfolio. The company announced the results on 24 January.
IP Group Plc, which invests in intellectual property generated by universities primarily in the UK, has decided to raise new capital with a share issue. Funds from the issue will enable the company to expand its portfolio of life science investments.
Seventure Partners, an indirect subsidiary of the French financial conglomerate, Natixis SA, has launched a new fund called Health for Life Capital that will invest in companies focused on nutrition and the science relating to the human microbiome.
JLL/Delta Dutch Newco BV, a company set up to combine the assets of Canada’s Patheon Inc and the pharmaceutical division of Royal DSM of the Netherlands, is raising $500 million with a private placement of eight-year notes in New York.
Venture capital-backed 4-Antibody AG of Switzerland is to be acquired by Agenus Inc of the US in a deal intended to exploit the Swiss company’s technology for producing antibodies that target checkpoint molecules, key regulators of the immune system.
Alkermes Plc is raising $250 million from a placement of its shares with the Invesco Perpetual Income Fund and the Invesco Perpetual High Income Fund. The placement comes three months after the company’s product for depression received ‘fast-track’ designation from the FDA.